NCT07323043 Effect of Tegileridine Versus Sufentanil as Analgesic Components on Opioid-Induced Cough During Anesthesia Induction
| NCT ID | NCT07323043 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First People's Hospital of Lianyungang |
| Condition | General Anesthetic Drug Adverse Reaction |
| Study Type | INTERVENTIONAL |
| Enrollment | 190 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2026-08-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 190 participants in total. It began in 2026-01-15 with a primary completion date of 2026-08-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients undergoing general anesthesia with planned tracheal intubation , a prospective, randomized, controlled study was conducted to record the occurrence of cough 2 minutes after injection of Sufentanil or Tegilerdine. The cough was graded based on the frequency and duration: Grade I, no cough; Grade II, a single mild cough; Grade III, multiple coughs with duration \<1 second; Grade IV, continuous coughing with a duration \>15 seconds.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 65 years, 18 ≤ BMI (kg/m²) ≤ 30; 2. ASA grade I \~ III; 3. Scheduled elective surgery under general anesthesia with tracheal intubation. Exclusion Criteria: 1. Patients with chronic cough (cough lasting \>8 weeks) or asthma; 2. Patients with a history of allergy to the drugs used during the study; 3. Patients with severe cardiovascular disease, intracranial lesions, eye lesions, or lung lesions.
Contact & Investigator
Xiaobao Zhang, Doctor
STUDY DIRECTOR
Xuzhou Medical University Affiliated Hospital of Lianyungang: Lianyungang No 1 People's Hospital
Frequently Asked Questions
Who can join the NCT07323043 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying General Anesthetic Drug Adverse Reaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07323043 currently recruiting?
Yes, NCT07323043 is actively recruiting participants. Contact the research team at hotdog100@163.coom for enrollment information.
Where is the NCT07323043 trial being conducted?
This trial is being conducted at Lianyungang, China.
Who is sponsoring the NCT07323043 clinical trial?
NCT07323043 is sponsored by The First People's Hospital of Lianyungang. The principal investigator is Xiaobao Zhang, Doctor at Xuzhou Medical University Affiliated Hospital of Lianyungang: Lianyungang No 1 People's Hospital. The trial plans to enroll 190 participants.